Hovione Names Vice-President of R&D
Hovione announced that it appointed a vice-president of R&D to work directly with client drug development projects.
On Jan. 12, 2015, Hovione announced that it appointed Filipe Gaspar, PhD, as vice-president of research and design (R&D) for the company. Gaspar, who will report to Hovione’s chief executive, Guy Villax, will lead teams that serve client drug development projects in Lisbon, Portugal, and New Jersey. Gaspar, a chemical engineer, joined Hovione in 2003 as a manufacturing engineer, and moved to R&D in 2004.
“We are very pleased to have Filipe running our R&D. Filipe brings great science and leadership skills. For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, know-how and ability to deliver,” said Guy Villax in a press release.
Source: Hovione
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
